NO20081354L - Dobbelt variabelt domeneimmunoglobin samt fremgangsmater derav - Google Patents

Dobbelt variabelt domeneimmunoglobin samt fremgangsmater derav

Info

Publication number
NO20081354L
NO20081354L NO20081354A NO20081354A NO20081354L NO 20081354 L NO20081354 L NO 20081354L NO 20081354 A NO20081354 A NO 20081354A NO 20081354 A NO20081354 A NO 20081354A NO 20081354 L NO20081354 L NO 20081354L
Authority
NO
Norway
Prior art keywords
methods
variable domain
double variable
domain immunoglobin
immunoglobin
Prior art date
Application number
NO20081354A
Other languages
English (en)
Norwegian (no)
Inventor
Jochen G Salfeld
Tariq Ghayur
Richard W Dixon
Chengbin Wu
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of NO20081354L publication Critical patent/NO20081354L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
NO20081354A 2005-08-19 2008-03-17 Dobbelt variabelt domeneimmunoglobin samt fremgangsmater derav NO20081354L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70991105P 2005-08-19 2005-08-19
US73289205P 2005-11-02 2005-11-02
PCT/US2006/032398 WO2007024715A2 (en) 2005-08-19 2006-08-18 Dual variable domain immunoglobin and uses thereof

Publications (1)

Publication Number Publication Date
NO20081354L true NO20081354L (no) 2008-05-16

Family

ID=41078242

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081354A NO20081354L (no) 2005-08-19 2008-03-17 Dobbelt variabelt domeneimmunoglobin samt fremgangsmater derav

Country Status (16)

Country Link
EP (4) EP2495257A3 (de)
JP (1) JP5364870B2 (de)
KR (2) KR20130108481A (de)
CN (1) CN101370525B (de)
AU (1) AU2006283532B2 (de)
BR (1) BRPI0615026A8 (de)
CA (1) CA2618482C (de)
IL (2) IL189543A (de)
MY (1) MY169746A (de)
NO (1) NO20081354L (de)
NZ (2) NZ597168A (de)
RU (2) RU2515108C2 (de)
SG (1) SG2014010029A (de)
TW (1) TWI323734B (de)
WO (1) WO2007024715A2 (de)
ZA (2) ZA201100659B (de)

Families Citing this family (512)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051438A2 (en) 2000-12-22 2002-07-04 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (rgm) and its modulators
TW200714610A (en) 2005-02-16 2007-04-16 Univ Maryland CXCR3 is a gliadin receptor
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP2012228248A (ja) * 2005-08-19 2012-11-22 Abbott Lab 二重可変ドメイン免疫グロブリン及びその使用
EP1928905B1 (de) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
MX2009008222A (es) 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
KR20200054317A (ko) 2007-02-09 2020-05-19 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
KR20100014724A (ko) 2007-03-30 2010-02-10 아보트 러보러터리즈 숙주 세포에서 재조합 단백질의 발현을 증강시키기 위한 재조합 발현 벡터 요소(ｒＥＶＥ)
WO2008134659A2 (en) 2007-04-27 2008-11-06 Zymogenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
WO2008145140A2 (en) 2007-05-31 2008-12-04 Genmab A/S Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
MX2009013194A (es) 2007-06-14 2010-03-30 Galactica Pharmaceuticals Inc Proteinas de fusion del receptor para productos finales de glicacion avanzada.
JP5403752B2 (ja) 2007-06-22 2014-01-29 北海道公立大学法人 札幌医科大学 移植片対宿主疾患の検査および治療方法
WO2009018386A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
WO2009021754A2 (en) * 2007-08-15 2009-02-19 Bayer Schering Pharma Aktiengesellschaft Monospecific and multispecific antibodies and method of use
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
EP2535349A1 (de) 2007-09-26 2012-12-19 UCB Pharma S.A. Antikörperfusionen mit Doppelspezifität
CN101970490A (zh) 2007-11-27 2011-02-09 埃博灵克斯股份有限公司 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
CL2008003561A1 (es) * 2007-11-30 2010-02-05 Glaxo Group Ltd Construccion de union a il - 13 que comprende a lo menos un dominio simple (dab) de anticuerpo injertado en un anticuerpo monoclonal ( mabdab); polinucleotido y celula huesped; procedimiento para preparar la construccion; composicion farmaceutica que la comprende y uso para tratar cancer o enfermedades inflamatorias.
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
WO2009088805A2 (en) 2008-01-03 2009-07-16 The Scripps Research Institute Antibody targeting through a modular recognition domain
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US20090202557A1 (en) * 2008-01-30 2009-08-13 Argiriadi Maria A Compositions and methods for crystallizing antibody fragments
US8962803B2 (en) * 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
ES2828627T3 (es) * 2008-04-25 2021-05-27 Kyowa Kirin Co Ltd Anticuerpo multivalente estable
KR20110014607A (ko) 2008-04-29 2011-02-11 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
NZ589434A (en) 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2297208A4 (de) * 2008-06-03 2012-07-11 Abbott Lab Dual-variable- domain-immunglobuline und ihre verwendungen
EA201170028A1 (ru) * 2008-07-02 2011-12-30 Эмерджент Продакт Дивелопмент Сиэтл, Ллс СВЯЗЫВАЮЩИЕ НЕСКОЛЬКО МИШЕНЕЙ БЕЛКИ, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКИМ ДЕЙСТВИЕМ TNF-α
CA2729949A1 (en) * 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2010028796A1 (en) * 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Trispecific hexavalent antibodies
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
AU2009298458B2 (en) 2008-09-30 2015-10-08 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
PT2894165T (pt) 2008-11-10 2023-03-17 Alexion Pharma Inc Métodos e composições para o tratamento de distúrbios associados ao complemento
CN102341411A (zh) 2008-12-31 2012-02-01 比奥根艾迪克Ma公司 抗-淋巴细胞毒素抗体
RU2011135768A (ru) * 2009-01-29 2013-03-10 Эбботт Лэборетриз Белки, связывающие il-1
CA2753287A1 (en) * 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
EP2403531A4 (de) 2009-03-05 2013-02-27 Abbott Lab Il-17-bindende proteine
CN104535765A (zh) * 2009-03-12 2015-04-22 癌症预防和治疗有限公司 鉴定、评估、预防以及治疗肺疾病的方法及试剂盒
AU2010232693B2 (en) 2009-03-30 2016-04-21 Acceleron Pharma Inc. BMP-ALK3 antagonists and uses for promoting bone growth
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
WO2010112194A1 (en) 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
AU2010233995A1 (en) 2009-04-07 2011-09-08 Roche Glycart Ag Bispecific anti-ErbB-2/anti-c-Met antibodies
EP2417159A1 (de) 2009-04-07 2012-02-15 Roche Glycart AG Bispezifische anti-erbb-3/anti-c-met-antikörper
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
US20110263827A1 (en) * 2009-05-01 2011-10-27 Abbott Laboratories Dual Variable Domain Immunnoglobulins and Uses Thereof
MX2011011670A (es) * 2009-05-01 2011-11-18 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las mismas.
WO2010129406A2 (en) * 2009-05-04 2010-11-11 The Johns Hopkins University Methods of promoting muscle growth
SG176219A1 (en) 2009-05-27 2011-12-29 Hoffmann La Roche Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
RU2012102021A (ru) 2009-06-23 2013-07-27 Алексион Фармасьютикалз, Инк. Биспецифические антитела, которые связываются с белками комплемента
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
MX2012002605A (es) 2009-08-29 2012-04-02 Abbott Lab Proteinas terapeutico de union a dll4.
BR112012004710A2 (pt) * 2009-09-01 2016-08-16 Abbott Lab imunoglobulinas de domínio variável duplo e uso das mesmas
EP2475682B1 (de) 2009-09-10 2018-01-31 UCB Biopharma SPRL Polyvalente antikörper
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
NZ598962A (en) 2009-09-16 2014-12-24 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
MX2012004415A (es) * 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US9487584B2 (en) 2009-11-11 2016-11-08 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (CLDN6)
SG10201501784YA (en) * 2009-12-07 2015-05-28 Univ Leland Stanford Junior Methods for enhancing anti-tumor antibody therapy
BR112012013734A2 (pt) 2009-12-08 2017-01-10 Abbott Gmbh & Co Kg anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina.
JP5234666B2 (ja) * 2009-12-11 2013-07-10 国立大学法人大阪大学 乾癬の判定のための測定方法
US20130059890A1 (en) * 2009-12-18 2013-03-07 Sydney West Area Health Service Antiviral agents
PL2516465T3 (pl) * 2009-12-23 2016-11-30 Przeciwciała anty-bv8 i ich zastosowania
MX2012008108A (es) 2010-01-11 2012-10-03 Alexion Pharma Inc Biomarcadores de efectos de inmunomodulacion en seres humanos tratados con anticuerpos anti-cd200.
SI2666872T1 (sl) * 2010-02-05 2016-08-31 Astute Medical, Inc. Postopki in sestavki za diagnozo in prognozo ledvične poškodbe in odpovedi ledvic
BR112012021941A2 (pt) 2010-03-02 2022-02-01 Abbvie Inc Proteínas terapêuticas de ligação a dll4
TW201144437A (en) * 2010-03-03 2011-12-16 Boehringer Ingelheim Int A-beta binding polypeptides
CA2792611A1 (en) * 2010-03-16 2011-09-22 Advanced Technologies And Regenerative Medicine, Llc Affinity peptides toward bmp-2
TR201903279T4 (tr) 2010-03-25 2019-03-21 Ucb Biopharma Sprl Disülfür stabilize edilmiş DVD-IG molekülleri.
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
LT3248462T (lt) 2010-03-31 2024-05-27 Ablexis, Llc Pelių genų inžinerija, skirta chimerinių antikūnų gamybai
RU2630663C9 (ru) * 2010-04-15 2017-11-29 Проджиникс Фармасьютикалс, Инк. Антитела для лечения ассоциированных с clostridium difficile инфекции и заболеваний
US9011852B2 (en) 2010-04-30 2015-04-21 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies
ES2949159T3 (es) 2010-05-06 2023-09-26 Novartis Ag Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6)
KR20130066631A (ko) 2010-05-06 2013-06-20 노파르티스 아게 치료적 저밀도 지단백질-관련 단백질 ６ （ｌｒｐ６） 다가 항체에 대한 조성물 및 사용 방법
KR101539684B1 (ko) * 2010-05-14 2015-07-27 애브비 인코포레이티드 Ｉｌ－１ 결합 단백질
AU2011270959A1 (en) 2010-06-22 2013-01-10 Musc Foundation For Research Development Antibodies to the C3d fragment of complement component 3
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
AU2011285852B2 (en) * 2010-08-03 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
AU2014246410B2 (en) * 2010-08-03 2016-06-16 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
JP2013537539A (ja) 2010-08-13 2013-10-03 ジェネンテック， インコーポレイテッド 疾患の治療のためのＩＬ−１β及びＩＬ−１８に対する抗体
CA2807278A1 (en) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
JP5753903B2 (ja) 2010-08-24 2015-07-22 ロシュ グリクアート アーゲー 活性化可能な二重特異性抗体
PE20140229A1 (es) 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
RU2710717C2 (ru) 2010-09-09 2020-01-10 Пфайзер Инк. Молекулы, связывающиеся с 4-1ВВ
CN101926998B (zh) * 2010-09-10 2013-09-04 中国科学院水生生物研究所 肾上腺素受体激动剂诱导胚胎型珠蛋白表达及其用途
WO2012057765A1 (en) * 2010-10-28 2012-05-03 The Board Of Regents Of The University Of Texas System Recombinant anti-cd19 monoclonal antibodies
EP3578568A3 (de) 2010-11-08 2020-01-08 Ablynx N.V. Cxcr2-bindende polypeptide
WO2012064771A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma, Inc. Actriia binding agents and uses thereof
US20130236467A1 (en) 2010-11-24 2013-09-12 Jeremy Griggs Multispecific antigen binding proteins targeting hgf
WO2012088094A2 (en) * 2010-12-21 2012-06-28 Abbott Laboratories Il-1 binding proteins
CA2821976A1 (en) * 2010-12-21 2012-09-13 Abbvie Inc. Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
EP2654792A4 (de) * 2010-12-22 2016-05-11 Abbvie Inc Zur hälfte immunoglobulin-bindende proteine und verwendungen davon
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
TW201242976A (en) * 2011-01-07 2012-11-01 Abbott Lab Anti-IL-12/IL-23 antibodies and uses thereof
DK3020730T3 (en) 2011-01-19 2019-04-15 Cantargia Ab ANTI-IL1RAP ANTIBODIES AND THEIR USE FOR TREATMENT OF SOLID TUMORS
AU2012212066A1 (en) 2011-02-03 2013-08-15 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
JP5918275B2 (ja) * 2011-02-08 2016-05-18 アッヴィ・インコーポレイテッド 変形性関節症及び疼痛の治療
CN102188707B (zh) * 2011-02-25 2015-08-05 中国医学科学院基础医学研究所 Il-17抑制剂在制备治疗流感的药物中的用途
CA2824824A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
MX341921B (es) 2011-02-28 2016-09-07 Hoffmann La Roche Proteinas de union a antigeno.
MX2013010011A (es) 2011-03-01 2014-10-24 Amgen Inc Agentes de unión biespecífica.
CN102757503A (zh) * 2011-04-28 2012-10-31 中国人民解放军第二军医大学 人前列腺凋亡反应蛋白4与凋亡素2配体融合蛋白的制法和用途
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
CN102253220B (zh) * 2011-06-07 2014-04-09 复旦大学附属中山医院 用于诊断慢性阻塞性肺病急性加重期的试剂盒
KR102111171B1 (ko) 2011-06-10 2020-05-14 메디뮨 엘엘씨 항슈도모나스 ｐｓｌ 결합 분자 및 그의 용도
CN102268089A (zh) * 2011-07-05 2011-12-07 上海交通大学 Agr2阻断抗体及其用途
DK2739748T3 (da) * 2011-08-05 2019-06-24 Univ Aix Marseille Il22ra2-gen med fibrosefølsomhed og anvendelser deraf
RU2605390C2 (ru) 2011-08-23 2016-12-20 Рош Гликарт Аг Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
JP6339015B2 (ja) * 2011-08-23 2018-06-06 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
CA2845147A1 (en) 2011-09-23 2013-03-28 Roche Glycart Ag Bispecific anti-egfr/anti igf-1r antibodies
CN104203978A (zh) 2011-10-24 2014-12-10 艾伯维股份有限公司 针对硬化蛋白的免疫结合剂
RU2014122602A (ru) 2011-11-04 2015-12-10 Новартис Аг Конструкции на основе белка, родственного липопротеинам низкой плотности, 6(lrp6), и удлинителя полупериода существования
KR102184343B1 (ko) 2011-11-07 2020-11-30 메디뮨 엘엘씨 항슈도모나스 ｐｓｌ 및 ｐｃｒｖ 결합 분자를 이용한 병용 요법
EP2776061B1 (de) * 2011-11-07 2019-08-14 MedImmune, LLC Multispezifische und multivalente bindungsproteine und verwendungen davon
MX359234B (es) * 2011-11-11 2018-09-20 Hutchinson Fred Cancer Res Inmunoterapia de celulas t objetivadas en ciclina a1 para cancer.
DK2780373T3 (da) * 2011-11-16 2019-11-04 Boehringer Ingelheim Int Anti-IL-36R-antistoffer
WO2013090635A2 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
WO2013090633A2 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
JP2015509704A (ja) * 2011-12-30 2015-04-02 アッヴィ・インコーポレイテッド 受容体に対する二重可変ドメイン免疫グロブリン
AU2012362326A1 (en) 2011-12-30 2014-07-24 Abbvie Inc. Dual variable domain immunoglobulins against IL-13 and/or IL-17
IL297229A (en) 2012-01-27 2022-12-01 Abbvie Inc The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells
WO2013119966A2 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
UA115781C2 (uk) * 2012-02-27 2017-12-26 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cx3cr1-зв'язуючий поліпептид
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
AU2013244999A1 (en) 2012-04-05 2014-09-25 F. Hoffmann-La Roche Ag Bispecific antibodies against human TWEAK and human IL17 and uses thereof
RU2018114903A (ru) 2012-04-06 2019-03-04 Омерос Корпорейшн Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения пароксизмальной ночной гемоглобинурии
AR090626A1 (es) * 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
US9062120B2 (en) 2012-05-02 2015-06-23 Janssen Biotech, Inc. Binding proteins having tethered light chains
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
KR20220100997A (ko) 2012-06-18 2022-07-18 오메로스 코포레이션 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
EP2867253B1 (de) 2012-06-27 2016-09-14 F. Hoffmann-La Roche AG Verfahren zur auswahl und herstellung massgeschneiderter, hochselektiver und multispezifischer targeting-einheiten mit mindestens zwei verschiedenen bindungseinheiten sowie verwendungen davon
BR112014028368A2 (pt) 2012-06-27 2017-11-14 Hoffmann La Roche método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
CN104394886B (zh) 2012-07-04 2017-05-24 弗·哈夫曼-拉罗切有限公司 抗茶碱抗体及使用方法
EP3339328A1 (de) 2012-07-04 2018-06-27 F. Hoffmann-La Roche AG Anti-biotin-antikörper und verwendungsverfahren
EP2869848B1 (de) 2012-07-04 2016-09-21 F. Hoffmann-La Roche AG Kovalent verknüpfte antigen-antikörper-konjugate
AR091755A1 (es) 2012-07-12 2015-02-25 Abbvie Inc Proteinas de union a il-1
HUE056217T2 (hu) 2012-07-13 2022-02-28 Roche Glycart Ag Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
BR112015007120A2 (pt) 2012-10-08 2017-12-12 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
SG11201503412RA (en) 2012-11-01 2015-05-28 Abbvie Inc Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
EP2935589A1 (de) 2012-12-18 2015-10-28 Novartis AG Zusammensetzungen und verfahren unter verwendung eines an hyaluronan bindenden peptid-tags
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
CN103103197A (zh) * 2013-01-30 2013-05-15 百奇生物科技（苏州）有限公司 抗cd138单克隆抗体可变区序列及其制备方法和应用
EP3626741A1 (de) 2013-02-20 2020-03-25 The Trustees Of The University Of Pennsylvania Behandlung von krebs mit humanisiertem chimärem anti-egfrviii-antigenrezeptor
EP3744736A1 (de) 2013-02-20 2020-12-02 Novartis AG Effektives targeting primärer humaner leukämie mit durch den chimären anti-cd123-antigen-rezeptor veränderten t-zellen
RU2015140915A (ru) 2013-02-26 2017-04-03 Роше Гликарт Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
KR101833602B1 (ko) 2013-02-26 2018-02-28 로슈 글리카트 아게 이중특이적 t 세포 활성화 항원 결합 분자
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JOP20140087B1 (ar) * 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
EP2970484B2 (de) * 2013-03-15 2022-09-21 Amgen Inc. Heterodimere bispezifische antikörper
WO2014144600A2 (en) 2013-03-15 2014-09-18 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
EP2970426B1 (de) 2013-03-15 2019-08-28 Michael C. Milone Anzielung zytotoxischer zellen mit chimären rezeptoren für eine adoptive immuntherapie
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
EP3000827B1 (de) * 2013-05-22 2020-04-22 Seoul National University Hospital Anti-tnf-alpha/cxcl10-doppeltargeting-antikörper und verwendung davon
SG10201800982QA (en) 2013-07-05 2018-03-28 Genmab As Humanized or chimeric cd3 antibodies
CN104341504B (zh) 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 双特异性抗体
CN104231086B (zh) * 2013-08-27 2019-12-13 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
CN103467605B (zh) * 2013-09-05 2015-02-04 武汉友芝友生物制药有限公司 一种cd3抗原及其制备方法和用途
KR20160055275A (ko) 2013-09-17 2016-05-17 유니버시티 헬스 네트워크 시스 ｒｇｍａ/네오제닌 상호작용 또는 지질 래프트에 대해 지시되는 제제 및 치료 방법에서의 이의 용도
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
CN104592390B (zh) * 2013-10-30 2017-11-10 上海张江生物技术有限公司 一类双特异重组抗HBsAg抗体、其制备方法及用途
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
CA3225453A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
CN105899533B (zh) 2013-12-20 2019-10-11 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
MX2016008191A (es) 2014-01-03 2017-11-16 Hoffmann La Roche Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente.
BR112016012666A2 (pt) 2014-01-03 2017-09-26 Hoffmann La Roche conjugado, anticorpos, formulação farmacêutica e usos de conjugado
JP6476194B2 (ja) 2014-01-03 2019-02-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重特異性抗ハプテン／抗血液脳関門受容体抗体、それらの複合体、及び血液脳関門シャトルとしてのそれらの使用
KR20160106684A (ko) 2014-01-10 2016-09-12 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 히드록시포름아미드 유도체 및 그의 용도
EP3097117B1 (de) 2014-01-21 2023-10-04 Novartis Ag Verbessertes antigen mit car-t-zellfähigkeit durch co-einführung von co-stimulatorischen molekülen
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2015113494A1 (zh) * 2014-01-28 2015-08-06 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
JP6712235B2 (ja) * 2014-02-24 2020-06-17 イミューンファルマ エッセ．エッレ．エッレ． 肺癌のためのバイオマーカー、その診断方法、およびキット
ES2857226T3 (es) 2014-03-15 2021-09-28 Novartis Ag Receptor de antígeno quimérico regulable
EP3593812A3 (de) 2014-03-15 2020-05-27 Novartis AG Behandlung von krebs mithilfe eines chimären antigenrezeptors
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
ES2915101T3 (es) 2014-03-27 2022-06-20 Bird Rock Bio Inc Anticuerpos que se unen al receptor cannabinoide 1 (CB1) humano
HUE054588T2 (hu) 2014-04-07 2021-09-28 Novartis Ag Rák kezelése CD19 elleni, kiméra antigénreceptor alkalmazásával
TWI707872B (zh) 2014-05-29 2020-10-21 美商宏觀基因股份有限公司 特異性結合多種癌症抗原的三特異性結合分子和其使用方法
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
WO2015198243A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
EP3161001A2 (de) 2014-06-25 2017-05-03 Novartis AG Il17-a spezifische antikörper die mit hyaluronan bindenden peptid-marker fusioniert sind
WO2015198240A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
CN112481283A (zh) 2014-07-21 2021-03-12 诺华股份有限公司 使用cd33嵌合抗原受体治疗癌症
EP3174546B1 (de) 2014-07-31 2019-10-30 Novartis AG Teilmengenoptimierte chimäre antigenrezeptorhaltige t-zellen
MA40510A (fr) 2014-08-04 2017-06-14 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
WO2016020880A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
JP6919118B2 (ja) 2014-08-14 2021-08-18 ノバルティス アーゲー ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
MY189028A (en) 2014-08-19 2022-01-20 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
GB201414823D0 (en) 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
EP3925622A1 (de) 2014-09-13 2021-12-22 Novartis AG Kombinationstherapien
AU2015317608B2 (en) 2014-09-17 2021-03-11 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
BR112017006602A2 (pt) 2014-10-01 2017-12-19 Medimmune Llc método de conjugação de um polipeptídeo
AU2015349610B2 (en) * 2014-11-17 2021-08-26 B-Creative Sweden Ab Method of treating or preventing stroke
PL3221359T3 (pl) 2014-11-17 2020-11-16 Regeneron Pharmaceuticals, Inc. Sposoby leczenia nowotworów przy użyciu dwuswoistego przeciwciała CD3XCD20
ES2835823T3 (es) 2014-11-20 2021-06-23 Hoffmann La Roche Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T para CD3 y para el receptor de folato 1 (FolR1) y antagonistas de la unión al eje de PD-1
CN105669867A (zh) * 2014-11-21 2016-06-15 上海中信国健药业股份有限公司 抗gitr/ctla-4双特异性抗体及其制备方法和用途
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
CA2969704C (en) 2014-12-05 2023-05-02 City Of Hope Cs1 targeted chimeric antigen receptor-modified t cells
US10982008B2 (en) * 2014-12-05 2021-04-20 Merck Patent Gmbh Domain-exchanged antibody
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
WO2016094834A2 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. A method for treating a complement mediated disorder caused by an infectious agent in a patient
TW201631152A (zh) 2014-12-29 2016-09-01 諾華公司 製造嵌合抗原受體－表現細胞之方法
US20160244520A1 (en) 2015-01-24 2016-08-25 Abbvie Inc. Compositions and methods for treating psoriatic arthritis
EP3250605A1 (de) 2015-01-26 2017-12-06 Cellectis Anti-hsp70-spezifische chimäre antigenrezeptoren (cars) für krebsimmuntherapie
JP6602875B2 (ja) 2015-01-26 2019-11-06 マクロジェニクス，インコーポレーテッド Ｄｒ５結合ドメインを含む多価分子
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CN105988009B (zh) * 2015-02-28 2018-03-13 复旦大学附属华山医院 Netrin‑4在制备检测胃癌及预后标志物的制剂中的用途
EP3070103A1 (de) * 2015-03-19 2016-09-21 Institut Hospitalier Universitaire De Strasbourg Monoklonale anti-claudin 1-antikörper zur vorbeugung und behandlung von hepatozellulärem karzinom
CN107646039B (zh) * 2015-04-02 2022-04-15 埃博灵克斯股份有限公司 具有有效抗hiv活性的双特异性cxcr4-cd4多肽
SI3280729T1 (sl) 2015-04-08 2022-09-30 Novartis Ag Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR)
ES2948133T3 (es) 2015-04-17 2023-08-31 Novartis Ag Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
TW201702271A (zh) 2015-04-30 2017-01-16 哈佛大學校長及研究員協會 治療代謝病症之抗－ａｐ２抗體及抗原結合劑
EP3289107A4 (de) 2015-05-01 2018-09-12 The University of British Columbia Biomarker für den nachweis von akuter abstossung bei einer herztransplantation
CN104987421A (zh) * 2015-05-13 2015-10-21 北京比洋生物技术有限公司 抗ctla-4和pd-1的双重可变结构域免疫球蛋白
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
EP3298033B2 (de) 2015-05-18 2023-07-12 TCR2 Therapeutics Inc. Zusammensetzungen und medizinische verwendung für tcr-programmierung mit fusionsproteinen
KR101997241B1 (ko) 2015-05-21 2019-07-09 하푼 테라퓨틱스, 인크. 삼중특이성 결합 단백질 및 사용 방법
PL3302520T4 (pl) 2015-06-04 2021-03-22 Ospedale San Raffaele S.R.L. IGFBP3 i jego zastosowania
EA033821B1 (ru) 2015-06-04 2019-11-29 Ospedale San Raffaele Srl Применение ингибитора оси igfbp3/tmem219 для лечения диабета
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
TWI737614B (zh) 2015-06-11 2021-09-01 博錸生技股份有限公司 已編碼微載體及其製造方法以及用以進行多工分析之包含該等已編碼微載體之套件
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2016207245A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
MX2017015908A (es) 2015-07-06 2018-03-15 Ucb Biopharma Sprl Anticuerpos de union a tau.
UA124616C2 (uk) 2015-07-06 2021-10-20 Юсб Біофарма Срл Зв'язуюче тау-білок антитіло
EP3325504A1 (de) 2015-07-21 2018-05-30 Novartis AG Verfahren zur verbesserung der wirksamkeit und expansion von immunzellen
IL297090A (en) 2015-07-30 2022-12-01 Macrogenics Inc Molecules that bind pd-1 and methods of using them
EP3331913A1 (de) 2015-08-07 2018-06-13 Novartis AG Behandlung von krebs mithilfe von chimären cd3-rezeptor-proteinen
AU2016320748B2 (en) 2015-09-09 2019-05-02 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
EP3347377B1 (de) 2015-09-09 2021-02-17 Novartis AG Thymus-stroma-lymphopoietin(tslp)-bindende antikörper und verfahren zur verwendung der antikörper
EP3347378A1 (de) 2015-09-11 2018-07-18 AbbVie Inc. Verfahren zur behandlung von rezidivierender multipler sklerose
WO2017044811A1 (en) 2015-09-11 2017-03-16 Bruce Andrien Recombinant glycosylated eculizumab and eculizumab variants
JP6990650B2 (ja) * 2015-09-17 2022-03-04 ザ スクリプス リサーチ インスティテュート 二重可変ドメインイムノコンジュゲートおよびその用途
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
ES2907486T3 (es) * 2015-09-24 2022-04-25 Univ North Carolina Chapel Hill Métodos y composiciones para reducir metástasis
MA43049A (fr) 2015-09-30 2018-08-08 Bird Rock Bio Inc Anticorps de liaison à un récepteur cannabinoïde 1 humain (cb1)
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
BR112018000835A2 (pt) 2015-10-02 2018-09-11 Hoffmann La Roche molécula, um ou mais polinucleotídeos, um ou mais vetores, célula, método de produção da molécula, composição, uso da molécula, método de tratamento de uma doença e método para induzir a lise de uma célula-alvo
WO2017062649A1 (en) 2015-10-07 2017-04-13 Alexion Pharmaceuticals, Inc. A method for treating age-related macular degeneration in a patient
EP3377526A1 (de) * 2015-11-18 2018-09-26 Merck Sharp & Dohme Corp. Pd1/ctla4-bindemittel
JP7118887B2 (ja) 2015-11-23 2022-08-16 ノバルティス アーゲー 最適化されたレンチウイルス移入ベクターおよびその使用
PL3387015T3 (pl) 2015-12-09 2022-02-14 F. Hoffmann-La Roche Ag Przeciwciało anty-CD20 typu II do ograniczania tworzenia przeciwciał przeciwlekowych
TWI758267B (zh) 2015-12-14 2022-03-21 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
CN106918699B (zh) * 2015-12-25 2018-07-06 广州瑞博奥生物科技有限公司 一种检测肾癌标记物的抗体芯片试剂盒
CN106661117B (zh) * 2015-12-30 2020-11-17 深圳先进技术研究院 IgG杂合型抗TNFα和IL-17A双特异性抗体
ES2944597T3 (es) 2015-12-30 2023-06-22 Novartis Ag Terapias con células efectoras inmunitarias de eficacia mejorada
CA3006529A1 (en) 2016-01-08 2017-07-13 F. Hoffmann-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
AU2017207318B2 (en) * 2016-01-11 2023-12-07 Inhibrx Biosciences, Inc. Multivalent and multispecific OX40-binding fusion proteins
AU2017207742B2 (en) 2016-01-11 2022-03-17 Inhibrx Biosciences, Inc. Multivalent and multispecific 41BB-binding fusion proteins
EP3851457A1 (de) 2016-01-21 2021-07-21 Novartis AG Gegen cll-1 gerichtete multispezifische moleküle
BR112018015259A2 (pt) 2016-01-27 2018-12-18 Medimmune Llc métodos para preparação de anticorpos com um padrão de glicosilação definido
CN105481981B (zh) * 2016-01-27 2019-03-19 中国人民解放军第二军医大学 靶向vegf双特异性抗体及其用途
WO2017142928A1 (en) 2016-02-17 2017-08-24 Macrogenics, Inc. Ror1-binding molecules, and methods of use thereof
WO2017149515A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
PE20231511A1 (es) 2016-03-22 2023-09-26 Hoffmann La Roche Moleculas biespecificas de celulas t activadas por proteasas que se unen especificamente al receptor 1 de folato (folr1) y cd3
EP3432924A1 (de) 2016-03-23 2019-01-30 Novartis AG Zellsekretierte minikörper und verwendungen davon
JP7208010B2 (ja) 2016-03-29 2023-01-18 ユニバーシティ オブ サザン カリフォルニア 癌を標的とするキメラ抗原受容体
BR112018071096A2 (pt) 2016-04-15 2019-02-26 Novartis Ag composições e métodos para a expressão da proteína seletiva
KR102514317B1 (ko) 2016-04-15 2023-03-27 마크로제닉스, 인크. 신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법
CN107347014B (zh) * 2016-05-04 2020-12-18 中国移动通信集团广东有限公司 一种网络故障检测方法和系统
GB201608197D0 (en) * 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
SG10201912563XA (en) 2016-05-27 2020-02-27 Agenus Inc Anti-tim-3 antibodies and methods of use thereof
JP2019517480A (ja) 2016-06-01 2019-06-24 アッヴィ・インコーポレイテッド 脊髄損傷及び疼痛を処置するための抗ＲＧＭａ（Ｒｅｐｕｌｓｉｖｅ Ｇｕｉｄａｎｃｅ Ｍｏｌｅｃｕｌｅ Ａ）アンタゴニスト抗体
US20170348442A1 (en) 2016-06-02 2017-12-07 Washington University Compositions and methods for detecting ccr2 receptors
US20210177896A1 (en) 2016-06-02 2021-06-17 Novartis Ag Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
CN106110426B (zh) * 2016-07-01 2019-01-22 翁炳焕 艾滋病免疫治疗仪
US20190336504A1 (en) 2016-07-15 2019-11-07 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
KR20230100748A (ko) 2016-07-28 2023-07-05 노파르티스 아게 키메라 항원 수용체 및 pd-1 억제제의 조합 요법
JOP20170154B1 (ar) 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
MX2019001469A (es) 2016-08-01 2019-10-02 Novartis Ag Tratamiento del cáncer usando un receptor de antígeno quimérico en combinación con un inhibidor de una molécula de macrófago pro- m2.
EP3494138A1 (de) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Zusammensetzungen und verfahren für tcr-programmierung mit fusionsproteinen
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018050902A2 (en) 2016-09-15 2018-03-22 Quadrucept Bio Limited Multimers, tetramers & octamers
CN107868791B (zh) * 2016-09-26 2021-11-23 阿思科力(苏州)生物科技有限公司 一种加强型Slit2 CAR-T和CAR-NK细胞制备方法和应用
ES2897217T3 (es) 2016-09-30 2022-02-28 Hoffmann La Roche Anticuerpos biespecíficos frente a p95HER2
AU2017339858B2 (en) 2016-10-03 2022-02-17 Abbott Laboratories Improved methods of assessing GFAP status in patient samples
TW202340473A (zh) 2016-10-07 2023-10-16 瑞士商諾華公司 利用嵌合抗原受體之癌症治療
DK3445787T3 (da) 2016-10-07 2021-03-01 Tcr2 Therapeutics Inc Sammensætninger og fremgangsmåder til omprogrammering af t-cellereceptorer under anvendelse af fusionsproteiner
ES2848206T3 (es) 2016-10-19 2021-08-05 Alexion Pharma Inc Un método de cuantificar C5 sin unir en una muestra
US11828683B2 (en) 2016-10-19 2023-11-28 Alexion Pharmaceuticals, Inc. Method of quantitating unbound C5a in a sample
AU2017363311A1 (en) 2016-11-22 2019-06-13 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
BR112019010602A2 (pt) 2016-11-23 2019-12-17 Harpoon Therapeutics Inc proteínas trispecíficas para psma e métodos de uso
WO2018098354A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
EP4252629A3 (de) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Verfahren, vorrichtungen und systeme zur detektion des magen-darm-trakts
WO2018107125A1 (en) 2016-12-09 2018-06-14 Seattle Genetics, Inc. Bivalent antibodies masked by coiled coils
KR102616436B1 (ko) 2016-12-14 2023-12-27 비오라 쎄라퓨틱스, 인크. Tnf 저해제로의 위장관 질환의 치료
EP3554541B1 (de) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Behandlung einer erkrankung des gastrointestinaltraktes mit einem chemokin/chemokin-rezeptor-inhibitor
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
EP3554343A1 (de) 2016-12-14 2019-10-23 Progenity, Inc. Behandlung einer erkrankung des gastrointestinaltraktes mit einem il-1-inhibitor
WO2018112235A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
CN117045784A (zh) 2016-12-14 2023-11-14 比奥拉治疗股份有限公司 使用利用可摄入装置释放的il-12/il-23抑制剂治疗胃肠道疾病
WO2018112223A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
CA3045931A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2018112255A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
EP4190318A1 (de) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Behandlung einer erkrankung des magen-darm-trakts mit einem jak-hemmer und vorrichtungen
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
CA3048211A1 (en) 2016-12-23 2018-06-28 Macrogenics, Inc. Adam9-binding molecules, and methods of use thereof
WO2018140725A1 (en) 2017-01-26 2018-08-02 Novartis Ag Cd28 compositions and methods for chimeric antigen receptor therapy
WO2018144535A1 (en) 2017-01-31 2018-08-09 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
CN106706930B (zh) * 2017-02-28 2018-11-02 扬州诺明哲天医学检验实验室有限公司 一种用于帕金森综合症检测的试剂盒
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CN106596979B (zh) * 2017-02-28 2018-10-09 汉氏联合（天津）干细胞研究院有限公司 一种用于帕金森综合症检测的试剂盒及其检测方法
JP7346300B2 (ja) 2017-03-23 2023-09-19 アボット・ラボラトリーズ 早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼｌ１を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
EP3600249A1 (de) 2017-03-30 2020-02-05 Progenity Inc. Behandlung von erkrankungen des magen-darm-traktes mit einem chst15-inhibitor
EP3600416B1 (de) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Behandlung einer erkrankung des gastrointestinaltraktes mit einem immunmodulatorischen mittel, das mit einer einnehmbaren vorrichtung freigesetzt wird.
WO2018183931A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
WO2018183941A2 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with live biotherapeutics
WO2018191531A1 (en) 2017-04-15 2018-10-18 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
WO2018200823A1 (en) 2017-04-28 2018-11-01 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US10730954B2 (en) 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
US10543271B2 (en) 2017-05-12 2020-01-28 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2018213335A1 (en) 2017-05-16 2018-11-22 Scalmibio, Inc. Activatable antibodies and methods of use thereof
US10866251B2 (en) 2017-05-25 2020-12-15 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
US11129564B2 (en) 2017-05-30 2021-09-28 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I
EP3638295A1 (de) 2017-06-13 2020-04-22 TCR2 Therapeutics Inc. Zusammensetzungen und verfahren zur tcr-reprogrammierung mithilfe von fusionsproteinen
US20190062428A1 (en) 2017-06-19 2019-02-28 Surface Oncology, Inc. Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
JP7454945B2 (ja) 2017-07-03 2024-03-25 アボット・ラボラトリーズ 血液中のユビキチンカルボキシ末端ヒドロラーゼｌ１レベルを測定するための、改善された方法
KR20200035966A (ko) 2017-07-11 2020-04-06 콤파스 테라퓨틱스 엘엘씨 인간 cd137에 결합하는 작동자 항체 및 이의 용도
CN111182951A (zh) 2017-08-01 2020-05-19 指南针制药有限责任公司 过滤和层析荚以及使用其的方法
CN107375904B (zh) * 2017-08-01 2020-11-27 无锡市人民医院 β-arrestin1在防治色素障碍性皮肤病中的应用
US20200306516A1 (en) 2017-08-14 2020-10-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof
US10927180B2 (en) 2017-10-13 2021-02-23 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
PE20201183A1 (es) 2017-10-13 2020-11-03 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso
EP3697436A1 (de) 2017-10-18 2020-08-26 Novartis AG Zusammensetzungen und verfahren für selektiven proteinabbau
SG11202003177RA (en) 2017-10-25 2020-05-28 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
US20190160102A1 (en) 2017-11-03 2019-05-30 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems for tumor growth inhibition
KR102189893B1 (ko) * 2017-11-15 2020-12-11 (주)에스엘에스바이오 bPAG1에 특이적으로 결합하는 항체 및 이의 용도
EP3713961A2 (de) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137-antikörper und tumorantigenbindende antikörper sowie deren verwendung
JP7344801B2 (ja) 2017-12-09 2023-09-14 アボット・ラボラトリーズ グリア原線維性酸性タンパク質（ｇｆａｐ）及び／又はユビキチンカルボキシ末端ヒドロラーゼｌ１（ｕｃｈ－ｌ１）を使用する、整形外科損傷を負っており、軽度外傷性脳損傷（ｔｂｉ）などの頭部への損傷を負ったか又は負った可能性がある対象についての診断及び査定の一助となるための方法
WO2019112860A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
BR112020011810A2 (pt) 2017-12-12 2020-11-17 Macrogenics, Inc. molécula de ligação cd16 x antígeno de doença, composição farmacêutica, uso da composição farmacêutica, e método para o tratamento de uma doença
CN109954136B (zh) * 2017-12-14 2023-05-02 深圳市中科艾深医药有限公司 人sDR5-Fc重组融合蛋白作为脑卒中治疗药物的应用
WO2019126536A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Humanized anti-cd200 antibodies and uses thereof
CA3082280A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
AU2018395255A1 (en) 2017-12-29 2020-06-11 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
US20190330591A1 (en) 2018-01-10 2019-10-31 Rubius Therapeutics, Inc. Amplifiable rnas for therapeutic cell systems
TWI802633B (zh) 2018-01-15 2023-05-21 大陸商南京傳奇生物科技有限公司 針對pd-1之單域抗體及其變異體
AR115360A1 (es) 2018-02-08 2021-01-13 Genentech Inc Moléculas de unión al antígeno y métodos de uso
US20210139582A1 (en) * 2018-02-13 2021-05-13 The Brigham And Women's Hospital, Inc. Therapeutic fcrn-based bispecific monoclonal antibodies
KR20230020023A (ko) 2018-03-14 2023-02-09 서피스 온콜로지, 인크. Cd39에 결합하는 항체 및 이의 용도
AU2018414456A1 (en) * 2018-03-22 2020-10-15 Universität Stuttgart Multivalent binding molecules
JP7328983B2 (ja) 2018-03-22 2023-08-17 サーフィス オンコロジー インコーポレイテッド 抗ｉｌ－２７抗体及びその使用
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
EP3784351A1 (de) 2018-04-27 2021-03-03 Novartis AG Car-t-zelltherapien mit erhöhter wirksamkeit
EP3788369A1 (de) 2018-05-01 2021-03-10 Novartis Ag Biomarker zur auswertung von car-t-zellen zur vorhersage des klinischen ergebnisses
CN108404132A (zh) * 2018-05-11 2018-08-17 厦门大学 Ifna4与ifna10基因在克罗恩病中的应用
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
CN108508216B (zh) * 2018-06-06 2020-08-07 暨南大学 抗人bFGF纳米抗体检测bFGF的方法及试剂盒
US20210123075A1 (en) 2018-06-08 2021-04-29 Novartis Ag Compositions and methods for immunooncology
KR20210020932A (ko) 2018-06-13 2021-02-24 노파르티스 아게 Bcma 키메라 항원 수용체 및 이의 용도
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
JP7397445B2 (ja) 2018-06-26 2023-12-13 協和キリン株式会社 Ｃｅｌｌ Ａｄｈｅｓｉｏｎ Ｍｏｌｅｃｕｌｅ３に結合する抗体
US11965035B2 (en) 2018-06-26 2024-04-23 Kyowa Kirin Co., Ltd. Antibody binding to chondroitin sulfate proteoglycan 5
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020033926A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
WO2020033923A1 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antigen binding agents that bind cd277 and uses thereof
WO2020033925A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
TW202019968A (zh) 2018-08-13 2020-06-01 美商英伊布里克斯公司 Ox40結合多肽及其用途
WO2020038963A1 (en) 2018-08-21 2020-02-27 Modiquest B.V. Antibodies binding to citrullinated histone 2a and/or 4
US20210253666A1 (en) 2018-08-30 2021-08-19 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CA3110513A1 (en) 2018-08-31 2020-03-05 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
EP3844265A2 (de) 2018-08-31 2021-07-07 Novartis AG Verfahren zur herstellung von zellen zur expression des chimären antigenrezeptors
TW202030323A (zh) 2018-08-31 2020-08-16 瑞士商諾華公司 製備表現嵌合抗原受體的細胞之方法
EP4268831A3 (de) 2018-09-12 2024-05-22 Fred Hutchinson Cancer Center Verminderung der cd33-expression zum selektiven schutz von therapeutischen zellen
IL297931A (en) 2018-09-25 2023-01-01 Harpoon Therapeutics Inc dll3 binding proteins and methods of use
US20220047633A1 (en) 2018-09-28 2022-02-17 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
US20210347851A1 (en) 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
MX2021004351A (es) 2018-10-16 2021-05-31 UCB Biopharma SRL Metodo para el tratamiento de miastenia grave.
AU2019379576A1 (en) 2018-11-13 2021-06-03 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
WO2020118011A1 (en) 2018-12-06 2020-06-11 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
JP2024504880A (ja) 2018-12-24 2024-02-02 サノフイ 疑似ｆａｂベースの多重特異性結合タンパク質
BR112021013571A2 (pt) 2019-01-16 2021-09-21 Compass Therapeutics Llc Formulações de anticorpos que se ligam a cd137 humano e usos das mesmas
GB201900732D0 (en) 2019-01-18 2019-03-06 Ucb Biopharma Sprl Antibodies
WO2020160020A1 (en) 2019-01-28 2020-08-06 Sanofi Methods of treating multiple myeloma
US20220144807A1 (en) 2019-02-15 2022-05-12 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3924055B1 (de) 2019-02-15 2024-04-03 Novartis AG Substituierte 3-(1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivate und verwendungen davon
WO2020172553A1 (en) 2019-02-22 2020-08-27 Novartis Ag Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
KR20210134339A (ko) 2019-02-25 2021-11-09 노파르티스 아게 바이러스 전달을 위한 메조다공성 실리카 입자 조성물
WO2020180695A1 (en) 2019-03-01 2020-09-10 Abbott Laboratories Methods for predicting major adverse cardiovascular events in subjects with coronary artery disease
MX2021011196A (es) 2019-03-15 2021-10-22 Cartesian Therapeutics Inc Receptores de antigenos quimericos anti-antigeno de maduracion de celulas b (anti-bcma).
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
CN109811064B (zh) * 2019-04-02 2023-12-05 华南农业大学 一种与鸡j亚群禽白血病抗性相关的分子标记及其应用
EP3953455A1 (de) 2019-04-12 2022-02-16 Novartis AG Verfahren zur herstellung von zellen zur expression des chimären antigenrezeptors
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
CN110075322B (zh) * 2019-05-20 2021-07-06 复旦大学附属妇产科医院 一种靶向GnRH受体的近红外荧光成像探针及其制备方法与应用
AU2020298572A1 (en) 2019-07-02 2021-11-18 Fred Hutchinson Cancer Center Recombinant Ad35 vectors and related gene therapy improvements
WO2021035170A1 (en) 2019-08-21 2021-02-25 Precision Biosciences, Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN110478474B (zh) * 2019-08-21 2020-06-02 启辰生生物科技(珠海)有限公司 免疫调节剂、疫苗、细胞及应用
BR112022002351A2 (pt) 2019-09-16 2022-07-19 Surface Oncology Inc Composições e métodos de anticorpo anti-cd39
CN110627905B (zh) * 2019-09-18 2021-04-27 中国医学科学院肿瘤医院 靶向vegf与egfr的双功能融合蛋白及其应用
WO2021062244A1 (en) 2019-09-25 2021-04-01 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof
CN110988354A (zh) * 2019-11-15 2020-04-10 同济大学 一种分泌蛋白Caspase1在早期心梗诊断试剂中的应用
EP4065158A2 (de) 2019-11-26 2022-10-05 Novartis AG Chimäre antigenrezeptoren bindende bcma und cd19 und verwendungen davon
GB201917480D0 (en) 2019-11-29 2020-01-15 Univ Oxford Innovation Ltd Antibodies
WO2021123996A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
IL294330A (en) 2020-01-06 2022-08-01 Vaccinex Inc Anti-ccr8 antibodies and their uses
US20230111593A1 (en) 2020-02-14 2023-04-13 Novartis Ag Method of predicting response to chimeric antigen receptor therapy
JP2023527609A (ja) 2020-02-21 2023-06-30 ハープーン セラピューティクス，インク． Ｆｌｔ３結合タンパク質および使用方法
BR112022017148A2 (pt) 2020-02-27 2022-11-08 Novartis Ag Métodos para produzir células que expressam receptor de antígeno quimérico
EP4110377A2 (de) 2020-02-27 2023-01-04 Novartis AG Verfahren zur herstellung von chimären antigenrezeptor exprimierenden zellen
CN111269326A (zh) 2020-02-28 2020-06-12 南京北恒生物科技有限公司 新型嵌合抗原受体及其用途
JP2023517889A (ja) 2020-03-10 2023-04-27 マサチューセッツ インスティテュート オブ テクノロジー ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
RU2763178C2 (ru) * 2020-03-23 2021-12-28 Акционерное Общество "Р-Фарм" Антитела для лабораторной диагностики концентрации интерлейкина-11
WO2021211331A1 (en) 2020-04-13 2021-10-21 Abbott Point Of Care Inc. METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
IL298114A (en) 2020-05-12 2023-01-01 Lyell Immunopharma Inc Chimeric antigen receptor spacers
CN111849910B (zh) 2020-05-27 2021-06-15 南京北恒生物科技有限公司 工程化免疫细胞及其用途
AU2021288224A1 (en) 2020-06-11 2023-01-05 Novartis Ag ZBTB32 inhibitors and uses thereof
WO2021249462A1 (zh) 2020-06-11 2021-12-16 南京北恒生物科技有限公司 表达nk抑制性分子的工程化免疫细胞及其用途
CN115916825A (zh) 2020-06-19 2023-04-04 豪夫迈·罗氏有限公司 与cd3和cd19结合的抗体
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
WO2022010798A1 (en) 2020-07-06 2022-01-13 Kiromic BioPharma, Inc. Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
JP2023527530A (ja) 2020-07-15 2023-06-29 南京北恒生物科技有限公司 同種異系移植のための操作された免疫細胞
IL299586A (en) 2020-07-16 2023-03-01 Novartis Ag Anti-betacellulin antibodies, their fragments, and multispecific binding molecules
CN114057890A (zh) 2020-07-31 2022-02-18 南京北恒生物科技有限公司 新型共刺激结构域及其用途
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20220043000A1 (en) 2020-08-04 2022-02-10 Abbott Laboratories Methods and kits for detecting sars-cov-2 protein in a sample
GB202012326D0 (en) 2020-08-07 2020-09-23 Citryll B V Diagnostic
CN112063588A (zh) 2020-08-13 2020-12-11 南京北恒生物科技有限公司 工程化免疫细胞及其用途
CA3188978A1 (en) 2020-08-21 2022-02-24 Sandeep Tharian Koshy Compositions and methods for in vivo generation of car expressing cells
CN114163532A (zh) 2020-09-10 2022-03-11 南京北恒生物科技有限公司 包含新型共刺激结构域的嵌合抗原受体及其用途
EP4229085A1 (de) 2020-10-13 2023-08-23 Almirall S.A. Bispezifische moleküle und behandlungsverfahren damit
AU2020475443A1 (en) 2020-11-02 2023-06-01 UCB Biopharma SRL Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
CN112300282A (zh) 2020-11-03 2021-02-02 南京北恒生物科技有限公司 靶向cd7的人源化抗体及其用途
CN114525259A (zh) 2020-11-03 2022-05-24 南京北恒生物科技有限公司 靶向cd7的嵌合抗原受体及其用途
CA3198447A1 (en) 2020-11-13 2022-05-19 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells
CA3202233A1 (en) 2020-11-18 2022-05-27 Kiromic BioPharma, Inc. Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
CN114524876A (zh) 2020-11-23 2022-05-24 南京北恒生物科技有限公司 靶向nkg2a的抗体及其用途
CA3198161A1 (en) 2020-12-01 2022-06-09 Beth MCQUISTON Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
CN112748247A (zh) * 2020-12-23 2021-05-04 复旦大学附属华山医院 抗体结合剂在制备白癜风病期辅助检测产品中的应用及白癜风病期鉴定用的检测试剂盒
WO2022147147A1 (en) 2020-12-30 2022-07-07 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
CN114763385A (zh) 2021-01-12 2022-07-19 南京北恒生物科技有限公司 靶向ror1的抗体及其用途
EP4273175A1 (de) 2021-02-03 2023-11-08 Bioheng Therapeutics Limited Neuartiger chimärer antigenrezeptor und verwendung davon
MX2023009100A (es) 2021-02-03 2023-09-25 Mozart Therapeutics Inc Agentes aglutinantes y métodos para usar los mismos.
CN112957472B (zh) * 2021-02-05 2021-11-16 无锡市第五人民医院 靶向ccl19/ccr7的乙型肝炎免疫治疗剂及其用途
KR20230148837A (ko) 2021-02-25 2023-10-25 라이엘 이뮤노파마, 인크. Ror1 표적화 키메라 항원 수용체
CN112961250B (zh) * 2021-03-01 2023-06-06 长春金赛药业有限责任公司 抗体融合蛋白及其应用
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CA3215049A1 (en) 2021-04-10 2022-10-13 Baiteng ZHAO Folr1 binding agents, conjugates thereof and methods of using the same
TW202308699A (zh) 2021-04-23 2023-03-01 美商普方生物製藥美國公司 Ｃｄ７０結合劑、其結合物及其使用方法
TW202309294A (zh) 2021-04-27 2023-03-01 瑞士商諾華公司 病毒載體生產系統
EP4085973A1 (de) 2021-05-04 2022-11-09 Citryll B.V. Hemmung von eosinophilen extrazellulären fallen
KR20240005856A (ko) 2021-05-04 2024-01-12 씨트릴 비.브이. 세포 외 트랩 억제
IL308198A (en) 2021-05-07 2024-01-01 Surface Oncology Llc Anti-IL-27 antibodies and uses thereof
WO2022245920A1 (en) 2021-05-18 2022-11-24 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
WO2022266034A1 (en) 2021-06-14 2022-12-22 Abbott Laboratories Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
TW202330598A (zh) * 2021-06-30 2023-08-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｂａｆｆ和ｉｌ－１２／２３的抗原結合分子及用途
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
EP4388000A1 (de) 2021-08-20 2024-06-26 Novartis AG Verfahren zur herstellung eines chimären antigenrezeptorsexpression von zellen
AU2022339759A1 (en) 2021-08-31 2024-03-07 Abbott Laboratories Methods and systems of diagnosing brain injury
CA3232176A1 (en) 2021-09-30 2023-04-06 Beth MCQUISTON Methods and systems of diagnosing brain injury
CN113884685B (zh) * 2021-10-18 2023-03-14 中国农业大学 牛结核病血清学诊断标志物及其临床应用
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
AU2022413677A1 (en) 2021-12-17 2024-06-27 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
WO2023129942A1 (en) 2021-12-28 2023-07-06 Abbott Laboratories Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
WO2023150652A1 (en) 2022-02-04 2023-08-10 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
TW202400658A (zh) 2022-04-26 2024-01-01 瑞士商諾華公司 靶向ｉｌ—１３和ｉｌ—１８的多特異性抗體
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
CN117285647A (zh) * 2022-06-17 2023-12-26 南京北恒生物科技有限公司 靶向ccr8的嵌合抗原受体及其用途
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same
WO2024059708A1 (en) 2022-09-15 2024-03-21 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
WO2024056809A1 (en) 2022-09-15 2024-03-21 Novartis Ag Treatment of autoimmune disorders using chimeric antigen receptor therapy
WO2024061158A1 (en) * 2022-09-20 2024-03-28 Everest Medicines (China) Co., Ltd. Slit2 related compositions and methods
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells
WO2024115393A1 (en) 2022-11-28 2024-06-06 UCB Biopharma SRL Treatment of fibromyalgia
US20240200085A1 (en) 2022-12-15 2024-06-20 Aarhus Universitet Synthetic activation of multimeric transmembrane receptors
CN116286669B (zh) * 2023-03-23 2023-09-22 江南大学 一株分泌托拉塞米单克隆抗体的杂交瘤细胞株及其应用

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US225A (en) 1837-06-03 Machine fob
US500362A (en) 1893-06-27 Resistance-box
US5780A (en) 1848-09-19 Improvement in preparing shoe-pegs
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
EP1186660A3 (de) 1985-03-30 2002-03-20 KAUFFMAN, Stuart A. Verfahren zum Erhalten von DNA, RNA, Peptiden, Polypeptiden oder Proteinen durch ein DNA-Rekombinations-Verfahren
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5763192A (en) 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (de) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Geänderte antikörper
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
ATE151110T1 (de) 1988-09-02 1997-04-15 Protein Eng Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
EP0478627A4 (en) 1989-05-16 1992-08-19 William D. Huse Co-expression of heteromeric receptors
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
CA2071867A1 (en) 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0542810A1 (de) 1990-08-02 1993-05-26 B.R. Centre Limited Verfahren zur herstellung von proteinen mit einer gewünschten funktion
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2105300C (en) 1991-03-01 2008-12-23 Robert C. Ladner Process for the development of binding mini-proteins
SK281142B6 (sk) 1991-03-06 2000-12-11 Merck Patent Gesellschaft Mit Beschr�Nkter Haftung Humanizovaná monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
JP3672306B2 (ja) 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート ファージミドを使用するヘテロ二量体受容体ライブラリー
AU666852B2 (en) 1991-05-01 1996-02-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
EP0519596B1 (de) 1991-05-17 2005-02-23 Merck & Co. Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4118120A1 (de) * 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
EP0590067A1 (de) 1991-06-14 1994-04-06 Xoma Corporation Mikrobiell hergestellte antikörper-fragmente und deren konjugate
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
US5766886A (en) 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
WO1995009917A1 (en) * 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5565352A (en) 1993-11-24 1996-10-15 Arch Development Corporation Deubiquitinating enzyme: compositions and methods
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
WO1995020401A1 (en) 1994-01-31 1995-08-03 Trustees Of Boston University Polyclonal antibody libraries
DE4408152A1 (de) 1994-03-11 1995-09-14 Studiengesellschaft Kohle Mbh Immobilisierte Lipasen in hydrophoben Sol-Gel-Materialien
ZA95960B (en) 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
SE9402430L (sv) * 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
WO1996020698A2 (en) 1995-01-05 1996-07-11 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Surface-modified nanoparticles and method of making and using same
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
JPH11503914A (ja) 1995-04-21 1999-04-06 セル ジェネシス，インコーポレイテッド 大ゲノムｄｎａ欠失の生成
EP1978033A3 (de) 1995-04-27 2008-12-24 Amgen Fremont Inc. Aus immunisiertem Xenomid abgeleitete menschliche Antikörper
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
CA2230494A1 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
US5989830A (en) * 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
AU2063197A (en) 1996-03-04 1997-09-22 Massachusetts Institute Of Technology Materials and methods for enhancing cellular internalization
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6015884A (en) * 1996-03-28 2000-01-18 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
EP0971946B1 (de) 1997-01-21 2006-07-05 The General Hospital Corporation Selektion von proteinen mittels rns-protein fusionen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
JP2002505097A (ja) 1998-03-03 2002-02-19 アブジェニックス インク． 治療薬としてのｃｄ１４７結合分子
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
NZ507381A (en) * 1998-04-21 2003-12-19 Micromet Ag CD19xCD3 specific polypeptides and uses thereof
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
CZ302706B6 (cs) 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
TR200102715T2 (tr) 1999-03-25 2002-09-23 Knoll Gmbh Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler.
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
TW201305214A (zh) 2000-02-10 2013-02-01 Abbott Gmbh & Co Kg 與人類間白素－１８結合之抗體，及其製法及用途
UA77157C2 (en) 2000-02-25 2006-11-15 Polypeptide anti-egfrviii scfvs with improved cytotoxicity and output, molecule of nucleic acid, that codes the indicated polypeptide, and method of cell destructure with using of this polypeptide
NZ521540A (en) * 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
AU5943201A (en) 2000-05-03 2001-11-12 Amgen Inc Modified peptides as therapeutic agents
AU2001258567A1 (en) 2000-05-19 2001-11-26 Scancell Limited Humanised antibodies to the epidermal growth factor receptor
JP2004511430A (ja) * 2000-05-24 2004-04-15 イムクローン　システムズ　インコーポレイティド 二重特異性免疫グロブリン様抗原結合蛋白および製造方法
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
AU7684201A (en) 2000-06-28 2002-01-08 Glycofi Inc Methods for producing modified glycoproteins
DE60137421D1 (de) 2000-06-29 2009-03-05 Abbott Lab Antikörper mit zwei spezifizitäten und verfahren zur deren herstellung und verwendung
CA2410551A1 (en) * 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
IL156618A0 (en) * 2000-12-28 2004-01-04 Altus Biologics Inc Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same
US20030157105A1 (en) 2001-05-30 2003-08-21 Carton Jill M. Anti-p40 immunglobulin derived proteins, compositions, methods and uses
DE10129336A1 (de) 2001-06-19 2003-01-02 Basf Ag Verfahren zur Herstellung von Pyrrolidonen
EP1432444A4 (de) 2001-08-17 2005-11-02 Lilly Co Eli Anti-a-beta-antikörper
WO2003029456A1 (en) 2001-10-01 2003-04-10 Dyax Corp. Multi-chain eukaryotic display vectors and uses thereof
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
JP4464395B2 (ja) 2003-03-05 2010-05-19 ヘイローザイム インコーポレイテッド 可溶性ヒアルロニダーゼ糖タンパク質（ｓＨＡＳＥＧＰ）、その調製プロセス、使用およびそれを含む薬学的組成物
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP1660534A2 (de) 2003-08-22 2006-05-31 MedImmune, Inc. Humanisierung von antikörpern
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
WO2005100584A2 (en) 2004-04-15 2005-10-27 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
EP1786918A4 (de) * 2004-07-17 2009-02-11 Imclone Systems Inc Neuer tetravalenter bispezifischer antikörper
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Also Published As

Publication number Publication date
AU2006283532B2 (en) 2012-04-26
MY169746A (en) 2019-05-14
RU2008110494A (ru) 2009-09-27
RU2014110927A (ru) 2015-09-27
EP2495257A2 (de) 2012-09-05
JP5364870B2 (ja) 2013-12-11
KR20140053410A (ko) 2014-05-07
NZ612578A (en) 2014-11-28
ZA201306105B (en) 2014-05-28
WO2007024715A9 (en) 2009-04-23
EP2500352A1 (de) 2012-09-19
EP1928506A4 (de) 2009-10-21
JP2009504191A (ja) 2009-02-05
CN101370525A (zh) 2009-02-18
BRPI0615026A8 (pt) 2018-03-06
RU2515108C2 (ru) 2014-05-10
IL189543A (en) 2014-06-30
BRPI0615026A2 (pt) 2009-06-16
CN101370525B (zh) 2013-09-18
EP1928506A2 (de) 2008-06-11
KR20130108481A (ko) 2013-10-02
ZA201100659B (en) 2012-12-27
TW200740849A (en) 2007-11-01
EP2495257A3 (de) 2012-10-17
SG2014010029A (en) 2014-08-28
CA2618482A1 (en) 2007-03-01
IL189543A0 (en) 2008-08-07
AU2006283532A1 (en) 2007-03-01
CA2618482C (en) 2014-10-07
WO2007024715A3 (en) 2008-10-30
TWI323734B (en) 2010-04-21
WO2007024715A2 (en) 2007-03-01
IL232646A0 (en) 2014-06-30
EP2520588A1 (de) 2012-11-07
NZ597168A (en) 2013-07-26

Similar Documents

Publication Publication Date Title
NO20081354L (no) Dobbelt variabelt domeneimmunoglobin samt fremgangsmater derav
WO2018091740A3 (en) Novel anti_cd137 antibodies and uses thereof
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
MX2018000590A (es) Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79).
NO20092130L (no) Tricykliske heteroarylforbindelser anvendelige som inhibitorer of januskinase
NO20074446L (no) DR5-antistoffer og anvendelser derav
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
CY1117317T1 (el) Αναστολεις κινασης janus για θεραπεια ξηροφθαλμιας και αλλων σχετικων με τον οφθαλμο ασθενειων
NO20065727L (no) Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
WO2010077422A3 (en) Formulations of single domain antigen binding molecules
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
EP2373692A4 (de) Immunglobuline mit zweifacher variabler domäne und ihre verwendung
SG151327A1 (en) Deazapurines useful as inhibitors of janus kinases
NO20072223L (no) Glykogenfosforylaseinhibitor forbindelser med farmsoytiske preparater av disse
NO20091326L (no) Indazolderivater som modulatorer av interleukin-1-reseptor-assosiert kinase
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
MX2009011810A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
DE602005020611D1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
MX2009012719A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
NO20083066L (no) Antistoffmolekyler med spesifisitet for human-IL-6
ATE474835T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ABBVIE INC., US

FC2A Withdrawal, rejection or dismissal of laid open patent application